Thus, p53 mutation has been used as a predictor to estimate whether the cancer cells are sensitive to Wee1 inhibitors in clinical trials (Indovina and Giordano, 2010; De Witt Hamer et al., 2011). This evidence concerns the gene WEE1 and cancer.